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1078–5Cardiovascular disease and death are major life-threatening problems in patients with atheromatous peripheral arterial
disease (PAD). This review focuses on management of hypertension in the context of cardiovascular risk in patients
with PAD. PAD is underdiagnosed and hypertension in PAD is often poorly managed. Current evidence supports
a low threshold for blood pressure treatment in PAD and intensive blood pressure control to reduce the high risk of
cardiovascular disease and death in patients with PAD. Optimal treatment targets should be <140/85 mmHg, with the
lower target of <130/80 mmHg in the presence of diabetes mellitus or chronic renal disease. Class-specific selection of
anti-hypertensive treatments in PAD should be based on caution in relation to co-existing renovascular disease and indi-
cations and contraindications based on other significant co-morbidity. There is a pressing need for primary end-point stud-
ies targeted specifically at patients with PAD. In particular, prospective studies in PAD are needed to obtain evidence for
benefits from specific blood pressure classes of treatment as well as the optimal blood pressure treatment target level. These
studies should consider impact in PAD of different demographic, risk factor, and co-morbidity profiles.
 2008 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Hypertension is a key risk factor for the development
of atheromatous peripheral arterial disease (PAD). In
patients presenting with PAD, hypertension is a ma-
jor associated cardiovascular risk factor, present in
up to 55% patients with PAD.1 Hypertension also
increases risk of cardiovascular disease (CVD) com-
plications and mortality in patients with established
PAD. Up to 5% of hypertensive patients have been
reported to have clinical evidence of peripheral
artery disease at presentation, with a marked age-
related increase in hypertension associated PAD.2
The main aim of this review is to consider choice
of treatment in the management of hypertension in
patients with PAD.sponding author. D. R. J. Singer, Professor of Clinical Pharma-
& Therapeutics, Clinical Sciences Research Institute, War-
edical School, University of Warwick, University Hospital,
d Bridge Road, Coventry CV2 2DX, United Kingdom.
address: mdscaf@warwick.ac.uk
884/000701 + 08 $34.00/0  2008 European Society for VasculaLevel of evidence
A major limitation of the literature on this topic is that
the evidence largely derives from sub-groups with
PAD studied within major outcome trials for patients
with high overall cardiovascular risk factor burden.
There are no within treatment class comparisons of ef-
fects on PAD-related disease end-points.Why worry about high blood pressure in peripheral
arterial disease?
Peripheral arterial disease is a manifestation of sys-
temic atherosclerosis that is common and often un-
der-diagnosed, and yet is associated with a high risk
of death and disabling ischaemic events. Patients
with PAD are at risk of blood pressure-attributable pro-
gression of the peripheral vascular problems. PAD is
also an independent predictor of increased risk of car-
diovascular and cerebrovascular death, with high
blood pressure a major reversible risk factor.3,4r Surgery. Published by Elsevier Ltd. All rights reserved.
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As for CVD, the major underlying risk factors for PAD
are cigarette smoking, hypertension, abnormal lipid
profile and diabetes mellitus.5e7 Untreated hyperten-
sion, and treated but uncontrolled hypertension, are
important risk factors for PAD, after adjustment for
other risk factors, with around a doubling in odds ra-
tio for presence of ABPI [ankle brachial pressure in-
dex] evidence of PAD, similar to the impact of
previous smoking, diabetes mellitus, or mild renal
failure.6 Systolic blood pressure after multivariate
analysis conferred an odds ratio for PAD of 1.3(CI
1.2e1.5) per 10 mmHg systolic pressure.7 It is impor-
tant therefore to consider ABPI monitoring in older
hypertensive patients especially those with cardiovas-
cular disease.Hypertension under treated in PAD
Blood pressure management in PAD tends to be poor.
In PARTNERS,5 hypertension was less often treated in
new (84%) and prior PAD (88%) compared to treat-
ment of hypertension in subjects with CVD (95%;
P< 0.001). This poor management extends to treat-
ment of other cardiovascular risk factors in subjects
with PAD.5Ethnicity, hypertension and PAD
The GENOA study8 reported that in older African-
Americans, the prevalence of diabetes, hypertension
and clinical PAD was higher and ABPI lower than
in non-Hispanic white subjects. African-American
ethnicity was a predictor of lower ABPI and clinical
PAD after adjusting for age and hypertension. A
higher prevalence of PAD in non-Hispanic black
men and women, and Mexican-American women
than non-Hispanic white men and women was re-
ported in NHANES.6 Higher risk ethnic groups
should assessed for presence of PAD and particular
attention paid to managing cardiovascular risk factors
in ethnic groups at higher risk of PAD.Secondary Hypertension in Patients with
Peripheral Arterial Disease
It is important to identify possible underlying causes
so that specific treatment may be targeted against
causes of hypertension where identified. Atheroma-
tous renal artery stenosis (RAS) is a common underly-
ing cause of hypertension in PAD.9,10 In a prospectiveEur J Vasc Endovasc Surg Vol 35, June 2008angiographic study of 629 patients with PAD, hyper-
tension was found in 63% of the patients in the group
with renal artery stenosis compared with 41% of con-
trols.11 There are large differences between studies in
prevalence of RAS in PAD. One explanation is that
some studies are retrospective. Geographical differ-
ences in ethnicity and risk factor burden may contrib-
ute, as may definitions of severe RAS, some reports
using at least 50% others at least 60% stenosis as thresh-
old definitions. As for other patients with hypertension,
patients with PAD may have other secondary causes of
hypertension including endocrine problems, such as
primary hyperaldosteronism and diabetes mellitus.12
Renal artery stenosis and PAD
There is controversy as to whether renal artery imag-
ing should be routinely performed in patients with
PAD and hypertension. PAD is an independent pre-
dictor of risk of vascular death however it is unclear
whether aggressive treatment of patients with PAD
and incidental RAS leads to clinical benefits.13 A prag-
matic approach is to image renal arteries in patients
with hypertension and more severe PAD, or in
patients with PAD and resistant hypertension and/
or renal impairment, in particular when there is pro-
gressive decline in renal function. The incidence of
RAS increases with increasing severity of PAD. After
adjustment for age and hypertension, RAS incidence
was 4 times greater in patients with 3e4 peripheral ar-
teries affected.9 Not all RAS is functionally significant.
However RAS is a major contributory cause of hyper-
tension in patients with PAD, prevalence dependent
on severity of renal artery narrowing. Wachtell
et al.,10 using aortography in 100 patients with severe
peripheral ischaemia found 81% [25/31] of patients
with RAS had hypertension. 13/14 patients (93%)
with a renal artery lumen reduction of >50% had hy-
pertension (P 0.001) compared with 12/17(71%) for
renal artery lumen diameter reduced by <50%.Lifestyle and Blood Pressure
Lifestyle measures are effective in preventing devel-
opment and reducing progression of hypertension.14
In the absence of specific studies in PAD, it would
be pragmatic to advise patients to adopt a multiple
life style approach to management of hypertension
in the context of overall cardiovascular risk. Reducing
sodium intake below 100 mmol/day, combined with
the Dietary Approaches to Stopping Hypertension
(DASH) diet, is more effective than either approach
alone in reducing both onset of hypertension and
703Hypertension and Peripheral Arterial Diseaseblood pressure in patients with milder hyperten-
sion.14 The DASH diet includes increased intake of
fruits, vegetables, low-fat dairy foods, potassium, cal-
cium, magnesium, dietary fibre and protein and in-
cludes whole grains, poultry, fish, and nuts. It also
includes less red meat, sweets, and sugar-containing
drinks than a typical Western diet.14 Long term reduc-
tion in dietary salt intake by 30e40 mmol/day in pa-
tients with pre-hypertension reduced both blood
pressure and cardiovascular events.15Diuretic-based treatment
Mild distal tubular diuretics in younger and elder
populations with uncomplicated hypertension reduce
a wide range of CVD endpoints.16 A thiazide was
used within the INVEST Trial (see below) as add-on
treatment, with evidence of overall endpoint benefit
from intensive blood pressure lowering.17 In patients
taking thiazide treatment it is important to monitor
blood glucose, uric acid, potassium and sodium levels
to anticipate possible metabolic cardiovascular effects
of treatment.Beta-blockers
Although beta-blockers would be expected to worsen
PAD by reducing muscle blood flow, there is no clear
evidence of long-term disadvantage of beta-blocker
treatment in PAD and some evidence that patients
with concomitant coronary artery disease have better
cardiovascular outcomes when treated with a beta-
blocker. A meta-analysis of randomised controlled
trials in PAD treated with beta-blockers reported no sig-
nificant worsening of intermittent claudication or
walking distance.18 However when combined, atenolol
and nifedipine reduced maximum walking distance by
9%, indicating the importance of context of beta-
blocker treatment.19 A capillary microscopy study20
reported no microcirculatory or symptom differences
between measurements obtained before and during
withdrawal of beta-blocking therapy, and again 2
weeks after re-introduction of beta-blocker treatment
in patients with intermittent claudication or ischaemic
rest pain and mild-moderate hypertension. Beta-
blocking drugs appear to be cardioprotective in pa-
tients with PAD however evidence is largely from
observational or unblinded randomised studies. Polde-
mans et al21 studied patients with abnormal stress
echocardiography who were undergoing elective ab-
dominal aortic or infra-inguinal arterial reconstruction.
Patients were randomised to receive standard care
alone or with the addition of bisoprolol treatment tobeta-blockade with bisoprolol. Adding bisoprolol re-
duced cardiac death or myocardial infarction after sur-
gery [0$30 (95% CI: 0$11e0$83)]. However the design
was open and beta-blockade was prescribed for car-
dio-protection, not hypertension. A separate prospec-
tive observational study22 reported that, in the
survivors of myocardial infarction, patients with inter-
mittent claudication not treated with beta-blockers had
3-fold mortality excess versus those receiving beta-
blockers. There is clinical interest in potential advan-
tages of beta-blockers such as nebivolol or carvedilol
with the additional property of vasodilation mediated
by nitric oxide release or anti-oxidant properties.23
Double-blind, randomised controlled studies are
needed to find to whether this additional mechanism
confers end-point benefits over other types of beta-
blocker in patients with PAD. It is unclear whether
cardio-protection applies to beta-blockade targeted at
hypertension in PAD, beyond that conferred by other
blood pressure-lowering treatments.
Although there are concerns about new onset of dia-
betes mellitus with beta-blocker treatment,24 it is cur-
rently recommended that beta-blockers should not be
withdrawn in patients with compelling indications for
beta-blockade, e.g. myocardial infarction or angina.25
If blood pressure therapy is initiated with a beta-blocker
and a second drug is required, BHS/NICE guidelines25
recommend adding a calcium-channel blocker rather
than a thiazide-type diuretic to reduce the patient’s
risk of developing diabetes. When a beta-blocker is
withdrawn, the dose should be reduced gradually to
avoid a rapid increase in sympathetic drive.25Calcium Channel Blocker [CCB] Treatment
Major options are dihydropyridines, which vasodilate
and increase renal sodium and water excretion and the
cardioselective CCBs diltiazem and phenylalkalamine
verapamil, which vasodilate, and reduce cardiac out-
put by reducing heart rate and force of cardiac con-
traction. In the VALUE Trial the primary outcomes
were cardiac morbidity and mortality26 with a primary
intention to assess response to treatment with the
angiotensin receptor blocker valsartan compared to
the dihydropyridine CCB amlodipine in the subgroup
of patients with PAD. There was no difference in com-
posite cardiac outcome in the1052 PAD patients
treated with valsartan and 1062 patients treated with
amlodipine.26 The Invest Trial (International Trando-
lapril Study) included 2699 PAD patients.17 The ACE
inhibitor trandolapril and diuretic hydrochlorothia-
zide were added to verapamil sustained release
(n¼ 1345) or beta-blocker (atenolol-based) initialEur J Vasc Endovasc Surg Vol 35, June 2008
704 D. R. J. Singer and A. Kitetreatment (n¼ 1354). Achieving a pressure <140
systolic or <90 diastolic reduced adverse cardiovascu-
lar outcomes [Hazard Ratio (HR): 0.82 or 0.70]. Com-
bining trandolapril with verapamil was associated
with fewer adverse outcomes than beta-blocker based
strategy [HR 0.79]. The inverse relationship between
ABPI and cardiovascular events was lost in subjects
undergoing intensive blood pressure treatment, sug-
gesting that the expected greater cardiovascular risk
associated with a lower ABPI is avoidable when blood
pressure is intensively lowered.17 The ABCD study in-
cluded patients with PAD associated with Type II dia-
betes. It reported a major benefit from tight vs. usual
BP control, irrespective of whether control was
achieved with a CCB (nisoldipine) or an ACEi (enalap-
ril). However the PAD sub-group was not powered to
allow comparison of independent effects of nisoldi-
pine or enalapril on cardiovascular outcomes.27ACE Inhibitor (ACEi) Treatment
The HOPE trial (Heart Outcomes Protection Evalua-
tion Study) is important in having a predefined PAD
hypothesis.28 Patients with PAD were followed for
4.5 years. 4051 of 9297 patients had PAD evidence
based on ABPI< 0.9, 1725 had clinical features of
PAD. The primary endpoint of death from vascular
causes or nonfatal myocardial infarction or non-fatal
stroke was reduced by ACEi treatment with ramipril
10 mg/day to 14.1% [placebo 17.7%]. Ramipril bene-
fits were about two-fold for low ABPI vs. ABPI> 0.9
(50/1000 events prevented: vs. 24/1000 events pre-
vented). A prospective observational study noted
that ACEi-based PAD treatment was associated with
reduced renal failure progression;4 since this was
not a randomised study, results should be treated
with caution. Effects of ACEi and angiotensin receptor
blockers may lead to clinical benefits independent of
blood pressure lowering. These effects include attenu-
ating the pleiotropic effects of angiotensin II such as
stimulation of oxidant stress, cardiovascular fibrosis,
vascular and cardiac muscle hypertrophy.29 However,
24 hour ambulatory blood pressure monitoring sug-
gested blood pressure decrease with ramipril could
have explained cardiovascular benefits. HOPE raises
the question about target blood pressure in PAD, as
many patients in HOPE had blood pressure below
the conventional hypertensive range.28 In significant
renal artery stenosis (RAS), blood flow within the af-
fected kidney or kidneys is critically dependent on lo-
cal levels of angiotensin II. In RAS, blocking the
synthesis of angiotensin II by inhibiting the enzyme
ACE or blocking the action of angiotensin II at theEur J Vasc Endovasc Surg Vol 35, June 2008receptor by using angiotensin type I receptor blocker
risks may cause significant renal impairment, risk of
heart failure and renal failure.30 The Utrecht group
noted a rise of >20% in creatinine in all patients
with bilateral RAS [n¼ 52] given ACEi treatment, af-
ter a delay from <4 days in 26 patients and <2 weeks
in 31 patients.30 The authors suggest that controlled
exposure to ACEi is safe in the setting of suspected
severe RAS, as no acute renal failure occurred and
creatinine always recovered on stopping treatment.
However in 12 patients, plasma creatinine only in-
creased after diuretic treatment was added to improve
blood pressure control.31 Furthermore renal failure
may develop in bilateral RAS within 36 hr of ACEi
treatment and renal function may not recover.31
Thus it is critically important in PAD that before using
ACEi or Angiotensin Receptor Blocker treatment
(ARB: see below), significant RAS is excluded and re-
nal function monitored regularly.Angiotensin Receptor Blockers (ARBs)
Selective blockade of the Type 2 receptor for angioten-
sin II inhibits angiotensin II mediated vasoconstriction,
aldosterone secretion, cardiovascular hypertrophy and
fibrosis and salt and water retention. The VALUE
study included specified sub-group analyses of the
primary endpoint according to history of peripheral
artery disease.26 The primary outcome measure of
cardiac morbidity and mortality was not significantly
different between the ARB valsartan (n¼ 1052) and
CCB amlodipine-based PAD treatment groups (1062),
although blood pressure reductions and myocardial
infarction incidence were significantly lower in the
amlodipine-based regimen.26
Alpha-blocker treatment
There is currently no primary endpoint data in PAD
populations with alpha blocker-based treatment.
However alpha blockers may be of practical benefit
in patients who have benign prostatic hypertrophy
by reducing symptoms and deferring need for sur-
gery. Furthermore, long-acting alpha blockers are
a pragmatically recognised agent as 4th line (step 4)
treatment in the 2006 BHS/NICE Guidelines where
treatment based on CCB, ACEi and diuretic is insuffi-
cient to achieve blood pressure control.25
Intensive vs. usual management of raised blood pressure
There is concern that critical blood pressure reduc-
tion may cause end-organ ischaemia by decreasing
705Hypertension and Peripheral Arterial Diseaseperfusion distal to occlusive atheromatous vascular
disease. Two studies suggest that intensive blood
pressure-lowering reduces high cardiovascular risk
in PAD, in the INVEST Trial [see above;17], by add-
ing ACEi and thiazide to prior treatment based on
the CCB verapamil or the beta-blocker atenolol;
in ABCD,27 for Type 2 diabetes, by adding the
CCB nisoldipine or ACEi enalapril [see CCB section
above].Compelling indications for class-specific selection
of anti-hypertensive agents
a) Impact of cardiovascular risk factors
There is little primary evidence on interaction be-
tween blood pressure lowering treatment and cardio-
vascular risk factors in patients with PAD. Thiazide
diuretics and beta-adrenergic blockers may adversely
affect lipid profile.24 However, thiazide associated
increase in lipid levels is dose-related and less of an
issue with modern use of low dose diuretics e.g. bend-
roflumethazide 2.5 mg or equivalent. Furthermore,
the relative risk from mild lipid profile abnormalities
appears greatly outweighed by the reduction in car-
diovascular end-points from anti-hypertensive treat-
ment with thiazides or beta-adrenergic blockers in
younger patients and for thiazide-based treatment
for hypertensive patients at least up to the age of
80.16,32 Beta-adrenergic blockers predispose to devel-
opment of diabetes mellitus and limit awareness of di-
abetic symptoms.24
b) Impact of co-morbidity on choice of treatment
(Table 1)
The impact of co-morbidity on choice of treatment
may be to provide a specific additional indication
for treatment, for example cardio-protection from
ACEi or beta-blockade following acute myocardial in-
farction, and value of alpha-adrenergic blockade to re-
duce symptoms of benign prostatic hypertrophy.24Table 1. Impact of co-morbidity on selection of blood pressure-lowe
Thiazide Potassium-sparing
diuretic
Beta-
blocke
Asthma or COPD Avoid
Renal artery stenosis Caution:
hyper-kalaemia risk
Renal failure Caution:
hyper-kalaemia risk
Diabetes mellitus Caution Cauti
Benign prostatic hypertrophy
Ischaemic heart disease Prefer
Heart failure Cauti
Heart block Avoid
CCB: calcium channel blocker. ACE: angiotensin converting enzyme.Co-morbidity may also suggest contra-indications in
view of potential adverse effects. Renal artery stenosis
should be excluded before exposure of patients to po-
tential risks of renal impairment if given a renin sys-
tem blocker (including beta-blocker, ACEi, ARB or
renin inhibition). Dihydropyridine CCBs should be
used with caution in patients with benign prostatic
hypertrophy as the resulting increase in urine flow
may increase symptoms of nocturia and polyuria.33
Beta-blockers exacerbate airways disease in patients
with asthma or chronic obstructive lung disease and
should therefore be avoided in these disorders. Other
contra-indications or cautions for beta-blockers in-
clude: avoidance in patients with heart block or on
drug treatment which predisposes to heart block; cau-
tion in diabetes mellitus in view of risk of masking
symptoms of hypoglycaemia; avoidance in acute heart
failure and caution in established heart failure.24,25National treatment guidelines
There are to date no specific national recommenda-
tions for choice of blood pressure therapy in periph-
eral arterial disease patients with hypertension.
However, it is widely accepted that existing guide-
lines should be used to help to provide the best pos-
sible medical care to patients with PAD. For
example, for the USA, this is based on a 7th revision
of JNC guidelines and for the UK in 2006, Scottish
SIGN guidelines34 and joint guidelines of the British
Hypertension Society and National Institute of Clini-
cal Healthcare Excellence (NICE).24,25 Other relevant
guidelines include those for Type 2 diabetes associ-
ated with hypertension [UK:NICE, 2002;35]. A further
relevant UK guideline entitled ‘‘Early identification
and management of adults with chronic kidney dis-
ease in primary and secondary care’’ is due for com-
pletion in September 2008. The latest BHS/NICE
hypertension guideline25 states that persistent raisedring treatment
r
CCB
dihydro-
pyridine
CCB
diltiazem or
verapamil
ACE inhibitor or
angiotensin receptor
blocker or renin inhibitor
Alpha
blocker
Avoid: renal failure risk
Caution: exclude
renal artery stenosis
on
Caution Preferred
red
on Avoid Preferred
Avoid
COPD: chronic obstructive pulmonary disease.
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should be treated, when after measurement at 2 sepa-
rate visits systolic, diastolic or both are above 140/
90 mmHg. The aim should be to reduce blood pres-
sure to an optimum target of below 140/85 mmHg.
Treatment should be based on lifestyle advice (see
above). In non-black patients, Step 1 treatment should
be with an ACE inhibitor if less than 55 years old,
with a calcium channel blocker or thiazide-type di-
uretic used if the patient is >55 years old, or for
a black patient of any age.25 Where additional treat-
ment is needed, appropriate add on treatments
should be used (see algorithm: Fig. 1). This may
help to explain the difference in outcomes in the IN-
VEST study,17 as a CCB (and not a beta-blocker) com-
bined with an ACE inhibitor is the rational
combination for effective blood pressure lower-
ing.24,25 The Type 2 diabetes and hypertension guide-
lines suggest that optimal blood pressure treatment
target is below 130/80 mmHg. In the presence of mi-
croalbuminuria, treatment with an ACE inhibitor is
recommended for combined cardiovascular and renal
protection.35Choosing drugs for treatment
with atheromatous perip
*A (B
younger than
*A=ACE inhibitor, 
Angiotensin Receptor Blocker
(B)=Beta-blocker –
indicated if history of 
myocardial infarction
C=Calcium channel blocker
^D=mild diuretic
*caution in view of high risk 
of renal artery stenosis
^caution with potassium-sparing diuretics 
in view of risk of renal
impairment in PAD
Fig. 1. Algorithm for blood pressure management in patients w
from British Hypertension Society/NICE Guidelines.25 ACE in
significant renovascular disease is suspected. At Step 4, potassi
the increased risk of renal impairment in patients with PAD.
Eur J Vasc Endovasc Surg Vol 35, June 2008Conclusions and strategy
Blood pressure treatment in PAD reduces cardiovascu-
lar morbidity and mortality. Intensive blood pressure
reduction provides significantly greater cardiovascu-
lar risk reduction than usual blood pressure manage-
ment. The HOPE trial suggests that lowering blood
pressure below conventional treatment thresholds in
patients with PAD is also effective in reducing cardio-
vascular risk.28 There is no clear level 1 evidence [low
bias prospective randomised control trial evidence;36]
that specific classes of treatment are to be preferred
in the absence of contra-indications or pressing indica-
tions because of co-morbidity [see above]. For inten-
sive blood pressure reduction, benefits appear
similar for dihydropyridine or ACE-inhibitor based
regimes.27
There is a pressing need for primary end-point
studies targeted specifically at patients with PAD, to
obtain evidence for blood pressure class and level re-
lated benefits for PAD in general and for PAD with
specific risk factor, demographic and co-morbidity
profiles. This will help to support development of hypertension in patients 
heral arterial disease
) C or D
*A + C + D
*A + C or *A + D
Add:
•   ^Further diuretic therapy
or
•   Alpha blocker
or
•   Beta blocker
Seek specialist advice
Step 1
Step 2
Step 3
Step 4
 55 years
55 years or older or 
African or Caribbean 
descent patients
of any age
ith atheromatous peripheral artery disease (PAD). Adapted
hibitors and ARBs should be used with caution if clinically
um sparing diuretics should be used with caution in view of
 Hypercalcaemia may be missed because se-
rum calcium is no longer routinely measured
in ‘routine’ blood samples. Clues include un-
707Hypertension and Peripheral Arterial Diseaseof evidence-based international guidelines on
medical management in PAD,35,37 with implementa-
tion supported by PAD networks and effective
Registries.5,38Text Box 1. General cardiovascular risk factor
burden
 This is poorly managed in peripheral arterial
disease.
 It is important to reduce blood pressure in the
context of overall cardiovascular risk to make
sure other risk factors are identified and
treated including hyperlipidaemia, smoking,
poor diabetic control and the need for effec-
tive anti-platelet treatment.
 For the latter it is important to consider risk of
GI bleed or intra-cerebral haemorrhage.
 Aspirin and other anti-platelet treatment
should be used with caution in a patient
whose blood pressure is not well-controlled.
Text Box 2. Renal artery stenosis
 Renal artery stenosis is common in patients
with PAD.
 clues include:
 increased severity of peripheral arterial
disease
 concomitant cardiovascular disease, for ex-
ample in the carotid or coronary circulation
 refractory hypertension
 impaired renal function. In patients with
RAS there is a major risk of acute renal im-
pairment or complete loss of renal function
if a patient is treated with an angiotensin
converting enzyme inhibitor or an angioten-
sin receptor antagonist.
Text Box 3. Other causes of hypertension
 Consider other causes of hypertension in pa-
tients with PAD e.g. endocrine hypertension
and intrinsic renal disease.
 High serum sodium and low serum potas-
sium indicate the need to exclude primary hy-
peraldosteronism (Conn’s syndrome).
explained nocturia, abdominal pains, joint
symptoms and confusion.
 Raised creatinine may be due to renal
disorders other than renovascular disease.Acknowledgements
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